TY  - CONF

T1  - Cost-effectiveness of adalimumab (Humira (TM)) in the treatment of US patients with rheumatoid arthritis (RA)

JO  - VALUE HEALTH

PY  - 2004/05/01

AU  - Bansback N

AU  - Brennan A

AU  - Sengupta N

ED  - 

VL  - 7

IS  - 3

SP  - 241

EP  - 241

Y2  - 2024/09/20

ER  -